Latest Ratios: P/E Ratio N/A · EV/EBITDA N/A · ROE 10.4%. (2023–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Market Cap | — | — | — |
| Enterprise Value | — | — | — |
| P/E Ratio → | — | — | — |
| P/S Ratio | — | — | — |
| P/B Ratio | — | — | — |
| P/FCF | — | — | — |
| P/OCF | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| EV / Revenue | — | — | — |
| EV / EBITDA | — | — | — |
| EV / EBIT | — | — | — |
| EV / FCF | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Gross Margin | 66.5% | 66.5% | — |
| Operating Margin | 48.8% | 48.8% | — |
| Net Profit Margin | 35.2% | 35.2% | — |
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| ROE | 10.4% | 10.4% | -0.5% |
| ROA | 6.6% | 6.6% | -0.4% |
| ROIC | 10.5% | 10.5% | -0.3% |
| ROCE | 9.5% | 9.5% | -0.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Debt / Equity | 0.12 | 0.12 | 0.01 |
| Debt / EBITDA | 0.22 | 0.22 | — |
| Net Debt / Equity | — | 0.12 | -0.00 |
| Net Debt / EBITDA | 0.22 | 0.22 | — |
| Debt / FCF | — | 0.03 | — |
| Interest Coverage | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Current Ratio | 16.98 | 16.98 | 0.80 |
| Quick Ratio | 16.98 | 16.98 | 0.80 |
| Cash Ratio | 0.00 | 0.00 | 0.76 |
| Asset Turnover | — | 0.22 | — |
| Inventory Turnover | — | — | — |
| Days Sales Outstanding | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Dividend Yield | — | — | — |
| Payout Ratio | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Earnings Yield | — | — | — |
| FCF Yield | — | — | — |
| Buyback Yield | — | — | — |
| Total Shareholder Yield | — | — | — |
| Shares Outstanding | — | $51M | $9M |
Extreme Liquidity and Reporting Discrepancies
As reported in recent financial filings, the company maintains high gross margins peaking at 70.4% in 2025Q3, yet these figures appear disconnected from consistent operational performance, suggesting that the reported profitability may be driven by non-recurring items rather than sustainable, core business activities within the biotech-food sector.
The wide variance in operating margins, which reached 58.0% in 2025Q3 before showing periods of inactivity, implies that the company lacks a stable cost-absorption mechanism. Investors should monitor whether these margins are truly reflective of product pricing power or merely an artifact of intermittent revenue recognition patterns.
Based on the provided financial data, the company's ROIC has fluctuated wildly from a negative 1.4% in 2025Q2 to a positive 29.3% in 2025Q3, indicating that the firm is currently unable to consistently compound capital or maintain a stable return profile for its shareholders.
This extreme volatility suggests that the company's capital allocation strategy is either highly reactive or potentially distorted by accounting anomalies. The inability to sustain positive returns on capital over consecutive quarters warrants further investigation into the underlying efficiency of the firm's R&D and operational investments.
According to the latest quarterly reports, the company's liquidity position is precarious, with current ratios swinging from 17.58 in 2024Q3 to near-zero levels in 2025Q2, signaling a severe lack of a cash buffer to support ongoing operations or mitigate potential short-term financial shocks.
The rapid depletion of liquid assets suggests that the company may be reliant on external financing or parent-company support to meet its immediate obligations. This lack of a stable liquidity floor makes the firm highly vulnerable to even minor disruptions in its revenue collection cycle.
As indicated by the historical financial statements, the most commonly misapplied metric for this entity is the P/E ratio, which fails to account for the extreme volatility in net income and the potential for non-operating distortions that frequently decouple earnings from actual cash-generating capacity.
Investors should instead focus on cash-based metrics or a rigorous analysis of working capital movements to understand the firm's true economic health. Relying on standard valuation multiples for a company with such erratic revenue and cash flow patterns may lead to a significant mispricing of the underlying business risk.
Includes 30+ ratios · 2 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying UCFIW stock.
CN Healthy Food Tech Group Corp.'s return on equity (ROE) is 10.4%. The historical average is 4.9%.
Based on historical data, CN Healthy Food Tech Group Corp. is trading at valuation metrics that vary. Compare with industry peers and growth rates for a complete picture.
CN Healthy Food Tech Group Corp. has 66.5% gross margin and 48.8% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
CN Healthy Food Tech Group Corp.'s Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.